Literature DB >> 8613193

Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation.

R Morishita1, J Higaki, N Tomita, M Aoki, A Moriguchi, K Tamura, K Murakami, Y Kaneda, T Ogihara.   

Abstract

Results of recent genetic studies suggest that the angiotensinogen gene is a possible determinant of hypertension. Using antisense technology, we demonstrated that generation of circulating angiotensinogen is a rate-limiting step in blood pressure regulation. In the present study, we examined how the angiotensinogen gene is regulated in vivo. The transcriptional cis-elements, angiotensinogen gene-activating elements (AGE) 2 and 3, have been reported to regulate angiotensinogen production in human hepatocytes in vitro. To determine the critical transcriptional regulator of angiotensinogen production in vivo, we used synthetic double-stranded oligodeoxynucleotides (ODN) as "decoy" cis-elements to block the binding of nuclear factors to promoter regions of the targeted gene, resulting in the inhibition of gene transactivation. Here we examined whether AGE 2 and AGE 3 in the promoter region of the angiotensinogen gene have a pivotal role in hepatic angiotensinogen production in vivo. Hepatic angiotensinogen mRNA was decreased by the transfection of AGE 2 but not mismatched decoy ODN. Transfection of decoy but not mismatched ODN against AGE 2 resulted in a transient decrease in blood pressure of spontaneously hypertensive rats (SHR), accompanied by a reduction in plasma angiotensinogen and angiotensin II levels. In contrast, transfection of AGE 3 decoy ODN had little effect on blood pressure. Overall, our results demonstrate that transfection of decoy ODN against AGE 2, but not against AGE 3, of the angiotensinogen gene resulted in a transient decrease in high blood pressure of SHR, suggesting that the transcriptional cis-element AGE 2, rather than AGE 3, has an important role in blood pressure regulation through the control of circulating angiotensinogen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613193     DOI: 10.1161/01.hyp.27.3.502

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor.

Authors:  K Tamura; Y E Chen; Q Chen; N Nyui; M Horiuchi; I Takasaki; N Tamura; R E Pratt; V J Dzau; S Umemura
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Authors:  Naruya Tomita; Naoki Kashihara; Ryuichi Morishita
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

Review 3.  Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?

Authors:  Kyung-Hyun Kim; Kwan-Kyu Park
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 4.  Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Authors:  Chia-Hua Wu; Ya Wang; Murong Ma; Adam E Mullick; Rosanne M Crooke; Mark J Graham; Alan Daugherty; Hong S Lu
Journal:  Biosci Rep       Date:  2019-01-11       Impact factor: 3.976

5.  Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.

Authors:  Alexander Perdomo-Pantoja; Sonia Iliana Mejía-Pérez; Nancy Reynoso-Noverón; Liliana Gómez-Flores-Ramos; Ernesto Soto-Reyes; Thalía Estefania Sánchez-Correa; Lissania Guerra-Calderas; Clementina Castro-Hernandez; Silvia Vidal-Millán; José Sánchez-Corona; Lucia Taja-Chayeb; Olga Gutiérrez; Bernardo Cacho-Diaz; Rosa Maria Alvarez-Gomez; Juan Luis Gómez-Amador; Patricia Ostrosky-Wegman; Teresa Corona; Luis Alonso Herrera-Montalvo; Talia Wegman-Ostrosky
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.